Improvement of Negative Symptoms in Schizophrenia with Paliperidone Palmitate 1-Month and 3-Month Long-Acting Injectables: Results from a Phase 3 Non-Inferiority Study

Srihari Gopal,1 Jagadish Gogate,1 Katalin Pungor,2 Edward Kim,3 Arun Singh,1 Maju Mathews1 1Janssen Research and Development, LLC, Titusville, NJ, USA; 2Medical Affairs, EMEA, Janssen-Cilag, Neuss, Germany; 3Janssen Scientific Affairs, Janssen Pharmaceuticals, Titusville, NJ, USACorrespondence: Srih...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Gopal S, Gogate J, Pungor K, Kim E, Singh A, Mathews M
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	negative symptoms paliperidone palmitate 3-month formulation paliperidone palmitate 1-month formulation. Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/c6dc97ae0664487db7899f4e59a3904f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c6dc97ae0664487db7899f4e59a3904f
record_format	dspace
spelling	oai:doaj.org-article:c6dc97ae0664487db7899f4e59a3904f2021-12-02T09:19:52ZImprovement of Negative Symptoms in Schizophrenia with Paliperidone Palmitate 1-Month and 3-Month Long-Acting Injectables: Results from a Phase 3 Non-Inferiority Study1178-2021https://doaj.org/article/c6dc97ae0664487db7899f4e59a3904f2020-03-01T00:00:00Zhttps://www.dovepress.com/improvement-of-negative-symptoms-in-schizophrenia-with-paliperidone-pa-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Srihari Gopal,1 Jagadish Gogate,1 Katalin Pungor,2 Edward Kim,3 Arun Singh,1 Maju Mathews1 1Janssen Research and Development, LLC, Titusville, NJ, USA; 2Medical Affairs, EMEA, Janssen-Cilag, Neuss, Germany; 3Janssen Scientific Affairs, Janssen Pharmaceuticals, Titusville, NJ, USACorrespondence: Srihari GopalJanssen Research and Development, LLC, 1125 Trenton Harbourton Road, Titusville, NJ 08560, USAEmail sgopal2@its.jnj.comBackground: Negative symptoms in schizophrenia are associated with impairments in social and cognitive functioning leading to substantial long-term disability. Available antipsychotic treatments have demonstrated only modest benefit in the improvement of negative symptoms.Objective: To compare improvements in negative symptoms among patients treated with paliperidone palmitate 3-month (PP3M) or paliperidone palmitate 1-month (PP1M) long-acting injectable (LAI) formulations.Methods: Data from a randomized double-blind (DB), phase-3, non-inferiority study in patients with schizophrenia were analyzed. Following screening, patients entered a 17-week open-label (OL) phase to receive flexibly dosed PP1M followed by a 48-week DB phase where patients were randomized (1:1) to receive either PP1M or PP3M. Positive and Negative Syndrome Scale (PANSS) total scores with emphasis on 7-item negative subscale scores for PP1M vs PP3M were assessed.Results: Of 1429 patients enrolled, 1016 were randomized to receive PP3M (n=504) or PP1M (n=512). At baseline, mean (SD) PANSS negative subscale was 23.2 (4.60) and negative symptom factor score was 22.3 (4.87), indicating moderate-to-severe negative symptoms. Negative subscale and symptoms factor scores showed continuous improvements throughout OL (15.9 [4.99]) and DB (14.9 [4.81]) phases. Mean (SD) changes from DB baseline in the PANSS negative subscale score were comparable between PP1M (– 1.4 [3.67]) and PP3M (– 1.4 [3.63]) treatment groups.Conclusion: Treatment with PP3M or PP1M demonstrated comparable improvement in negative symptoms in patients with moderate-to-severe negative symptoms and in patients with prominent negative symptoms. Long-term treatment with PP3M demonstrated benefit, suggesting that continuous antipsychotic medication treatment for > 1 year is needed to achieve greater benefit for negative symptoms.Trial Registration: ClinicalTrials.gov Identifier: NCT01515423.Keywords: negative symptoms, paliperidone palmitate 3-month formulation, paliperidone palmitate 1-month formulationGopal SGogate JPungor KKim ESingh AMathews MDove Medical Pressarticlenegative symptomspaliperidone palmitate 3-month formulationpaliperidone palmitate 1-month formulation.Neurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 16, Pp 681-690 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	negative symptoms paliperidone palmitate 3-month formulation paliperidone palmitate 1-month formulation. Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	negative symptoms paliperidone palmitate 3-month formulation paliperidone palmitate 1-month formulation. Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Gopal S Gogate J Pungor K Kim E Singh A Mathews M Improvement of Negative Symptoms in Schizophrenia with Paliperidone Palmitate 1-Month and 3-Month Long-Acting Injectables: Results from a Phase 3 Non-Inferiority Study
description	Srihari Gopal,1 Jagadish Gogate,1 Katalin Pungor,2 Edward Kim,3 Arun Singh,1 Maju Mathews1 1Janssen Research and Development, LLC, Titusville, NJ, USA; 2Medical Affairs, EMEA, Janssen-Cilag, Neuss, Germany; 3Janssen Scientific Affairs, Janssen Pharmaceuticals, Titusville, NJ, USACorrespondence: Srihari GopalJanssen Research and Development, LLC, 1125 Trenton Harbourton Road, Titusville, NJ 08560, USAEmail sgopal2@its.jnj.comBackground: Negative symptoms in schizophrenia are associated with impairments in social and cognitive functioning leading to substantial long-term disability. Available antipsychotic treatments have demonstrated only modest benefit in the improvement of negative symptoms.Objective: To compare improvements in negative symptoms among patients treated with paliperidone palmitate 3-month (PP3M) or paliperidone palmitate 1-month (PP1M) long-acting injectable (LAI) formulations.Methods: Data from a randomized double-blind (DB), phase-3, non-inferiority study in patients with schizophrenia were analyzed. Following screening, patients entered a 17-week open-label (OL) phase to receive flexibly dosed PP1M followed by a 48-week DB phase where patients were randomized (1:1) to receive either PP1M or PP3M. Positive and Negative Syndrome Scale (PANSS) total scores with emphasis on 7-item negative subscale scores for PP1M vs PP3M were assessed.Results: Of 1429 patients enrolled, 1016 were randomized to receive PP3M (n=504) or PP1M (n=512). At baseline, mean (SD) PANSS negative subscale was 23.2 (4.60) and negative symptom factor score was 22.3 (4.87), indicating moderate-to-severe negative symptoms. Negative subscale and symptoms factor scores showed continuous improvements throughout OL (15.9 [4.99]) and DB (14.9 [4.81]) phases. Mean (SD) changes from DB baseline in the PANSS negative subscale score were comparable between PP1M (– 1.4 [3.67]) and PP3M (– 1.4 [3.63]) treatment groups.Conclusion: Treatment with PP3M or PP1M demonstrated comparable improvement in negative symptoms in patients with moderate-to-severe negative symptoms and in patients with prominent negative symptoms. Long-term treatment with PP3M demonstrated benefit, suggesting that continuous antipsychotic medication treatment for > 1 year is needed to achieve greater benefit for negative symptoms.Trial Registration: ClinicalTrials.gov Identifier: NCT01515423.Keywords: negative symptoms, paliperidone palmitate 3-month formulation, paliperidone palmitate 1-month formulation
format	article
author	Gopal S Gogate J Pungor K Kim E Singh A Mathews M
author_facet	Gopal S Gogate J Pungor K Kim E Singh A Mathews M
author_sort	Gopal S
title	Improvement of Negative Symptoms in Schizophrenia with Paliperidone Palmitate 1-Month and 3-Month Long-Acting Injectables: Results from a Phase 3 Non-Inferiority Study
title_short	Improvement of Negative Symptoms in Schizophrenia with Paliperidone Palmitate 1-Month and 3-Month Long-Acting Injectables: Results from a Phase 3 Non-Inferiority Study
title_full	Improvement of Negative Symptoms in Schizophrenia with Paliperidone Palmitate 1-Month and 3-Month Long-Acting Injectables: Results from a Phase 3 Non-Inferiority Study
title_fullStr	Improvement of Negative Symptoms in Schizophrenia with Paliperidone Palmitate 1-Month and 3-Month Long-Acting Injectables: Results from a Phase 3 Non-Inferiority Study
title_full_unstemmed	Improvement of Negative Symptoms in Schizophrenia with Paliperidone Palmitate 1-Month and 3-Month Long-Acting Injectables: Results from a Phase 3 Non-Inferiority Study
title_sort	improvement of negative symptoms in schizophrenia with paliperidone palmitate 1-month and 3-month long-acting injectables: results from a phase 3 non-inferiority study
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/c6dc97ae0664487db7899f4e59a3904f
work_keys_str_mv	AT gopals improvementofnegativesymptomsinschizophreniawithpaliperidonepalmitate1monthand3monthlongactinginjectablesresultsfromaphase3noninferioritystudy AT gogatej improvementofnegativesymptomsinschizophreniawithpaliperidonepalmitate1monthand3monthlongactinginjectablesresultsfromaphase3noninferioritystudy AT pungork improvementofnegativesymptomsinschizophreniawithpaliperidonepalmitate1monthand3monthlongactinginjectablesresultsfromaphase3noninferioritystudy AT kime improvementofnegativesymptomsinschizophreniawithpaliperidonepalmitate1monthand3monthlongactinginjectablesresultsfromaphase3noninferioritystudy AT singha improvementofnegativesymptomsinschizophreniawithpaliperidonepalmitate1monthand3monthlongactinginjectablesresultsfromaphase3noninferioritystudy AT mathewsm improvementofnegativesymptomsinschizophreniawithpaliperidonepalmitate1monthand3monthlongactinginjectablesresultsfromaphase3noninferioritystudy
_version_	1718398147981475840

Improvement of Negative Symptoms in Schizophrenia with Paliperidone Palmitate 1-Month and 3-Month Long-Acting Injectables: Results from a Phase 3 Non-Inferiority Study

Ejemplares similares